About Alizé Pharma
Alizé Pharma is a company based in Ecully (France) founded in 2007 was acquired by Millendo Therapeutics in December 2017. Alizé Pharma has raised $94.35 million across 7 funding rounds from investors including Crédit Agricole, Orbimed and Bpifrance. Alizé Pharma offers products and services including Enhertu and AstraZeneca Vaccines.
- Headquarter Ecully, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$94.35 M (USD)
in 7 rounds
-
Latest Funding Round
$75 M (USD), Series A
Jul 31, 2019
-
Investors
Crédit Agricole
& 14 more
-
Employee Count
Not available
-
Acquired by
Millendo Therapeutics
(Dec 20, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alizé Pharma
Alizé Pharma offers a comprehensive portfolio of products and services, including Enhertu and AstraZeneca Vaccines.
Targets HER2-positive metastatic breast cancer for improved progression-free survival
Develops vaccines and therapies for infectious diseases and immune protection
Funding Insights of Alizé Pharma
Alizé Pharma has successfully raised a total of $94.35M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $75 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alizé Pharma
Alizé Pharma has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Crédit Agricole, Orbimed and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in life sciences businesses are managed.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Biotech startups are funded through venture capital in life sciences.
|
Locked | Locked | Locked |
Investor details for Alizé Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alizé Pharma
Investment portfolio details for Alizé Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alizé Pharma
Detailed financials for Alizé Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alizé Pharma Comparisons
Peer comparison for Alizé Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alizé Pharma
Detailed competitors of Alizé Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alizé Pharma
Complete news archive for Alizé Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alizé Pharma
Alizé Pharma was founded in 2007.
Alizé Pharma is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.
Alizé Pharma is a funded company, having raised a total of $94.35M across 7 funding rounds to date.
Alizé Pharma was established in 2007 in Ecully, France, within the biotechnology sector. Emphasis is placed on the development of drugs, proteins, and peptides targeted at metabolic and rare diseases. Research and development operations are conducted to create therapeutic solutions for these conditions, with activities focused on addressing specific unmet needs in patient care across Europe.
Alizé Pharma offers Enhertu and AstraZeneca Vaccines.
Alizé Pharma has 15 investors. Key investors include Crédit Agricole, Orbimed, Bpifrance, Kurma Partners, and Life Sciences Partners.